Krystal Biotech Inc

For the period ended Dec 31, 2023. Filed Feb 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 26, 2024

KRYS$306.50+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of and

Consolidated Balance Sheets

(In thousands, except shares and par value data)	December 31,2023	December 31,2022
Assets
Current assets
Cash and cash equivalents	$358,328	$161,900
Short-term investments	173,850	217,271
Accounts receivable, net	42,040	—
Inventory	6,985	—
Prepaid expenses and other current assets	6,706	4,608
Total current assets	587,909	383,779
Property and equipment, net	161,202	161,684
Long-term investments	61,954	4,621
Right-of-use assets	7,027	8,042
Other non-current assets	263	324
Total assets	$818,355	$558,450
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$4,132	$3,981
Current portion of lease liability	1,474	1,561
Accrued expenses and other current liabilities	27,488	23,305
Total current liabilities	33,094	28,847
Lease liability	6,620	7,372
Total liabilities	39,714	36,219
Commitments and contingencies (Note 7)
Stockholders' equity
Common stock; $0.00001 par value; 80,000,000 shares authorized at December 31,2023 and 2022; 28,236,673 and 25,763,743 shares issued and outstanding at December 31, 2023 and 2022, respectively	—	—
Additional paid-in capital	1,047,830	803,718
Accumulated other comprehensive gain (loss)	638	(728)
Accumulated deficit	(269,827)	(280,759)
Total stockholders' equity	778,641	522,231
Total liabilities and stockholders' equity	$818,355	$558,450

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.